Humasis Co. Ltd. (KOSDAQ:205470)

Market Cap	130.35B
Revenue (ttm)	35.60B
Net Income (ttm)	-37.58B
Shares Out	113.15M
EPS (ttm)	-364.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	708,256
Average Volume	770,655
Open	1,152.00
Previous Close	1,152.00
Day's Range	1,139.00 - 1,159.00
52-Week Range	1,139.00 - 2,175.00
Beta	0.07
RSI	34.97
Earnings Date	Nov 14, 2025

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2000
• Employees: 69
• Stock Exchange: KOSDAQ
• Ticker Symbol: 205470

Financial Performance

In 2024, Humasis's revenue was 25.41 billion, an increase of 83.79% compared to the previous year's 13.83 billion. Losses were -30.44 billion, -45.08% less than in 2023.